Martin Elodie, Aigrot Marie-Stéphane, Grenningloh Roland, Stankoff Bruno, Lubetzki Catherine, Boschert Ursula, Zalc Bernard
Sorbonne Université, Inserm, CNRS, Institut du Cerveau et de la Moelle Épinière, GH Pitié-Salpêtrière, F-75013 Paris, France.
EMD Serono Research & Development Institute, Inc., Billerica, MA, United States (a business of Merck KGaA, Darmstadt, Germany).
Brain Plast. 2020 Oct 1;5(2):123-133. doi: 10.3233/BPL-200100.
Microglia are the resident macrophages of the central nervous system (CNS). In multiple sclerosis (MS) and related experimental models, microglia have either a pro-inflammatory or a pro-regenerative/pro-remyelinating function. Inhibition of Bruton's tyrosine kinase (BTK), a member of the Tec family of kinases, has been shown to block differentiation of pro-inflammatory macrophages in response to granulocyte-macrophage colony-stimulating factor . However, the role of BTK in the CNS is unknown.
Our aim was to investigate the effect of BTK inhibition on myelin repair in and experimental models of demyelination and remyelination. The remyelination effect of a BTK inhibitor (BTKi; BTKi-1) was then investigated in LPC-induced demyelinated cerebellar organotypic slice cultures and metronidazole-induced demyelinated transgenic tadpoles.
Cellular detection of BTK and its activated form BTK-phospho-Y223 (p-BTK) was determined by immunohistochemistry in organotypic cerebellar slice cultures, before and after lysophosphatidylcholine (LPC)-induced demyelination. A low BTK signal detected by immunolabeling under normal conditions in cerebellar slices was in sharp contrast to an 8.5-fold increase in the number of BTK-positive cells observed in LPC-demyelinated slice cultures. Under both conditions, approximately 75% of cells expressing BTK and p-BTK were microglia and 25% were astrocytes. Compared with spontaneous recovery, treatment of demyelinated slice cultures and MTZ-demyelinated transgenic tadpoles with BTKi resulted in at least a 1.7-fold improvement of remyelination.
Our data demonstrate that BTK inhibition is a promising therapeutic strategy for myelin repair.
小胶质细胞是中枢神经系统(CNS)的常驻巨噬细胞。在多发性硬化症(MS)及相关实验模型中,小胶质细胞具有促炎或促再生/促髓鞘再生功能。已表明抑制布鲁顿酪氨酸激酶(BTK),即Tec激酶家族的一员,可阻断促炎巨噬细胞对粒细胞-巨噬细胞集落刺激因子的分化反应。然而,BTK在中枢神经系统中的作用尚不清楚。
我们的目的是研究BTK抑制对脱髓鞘和髓鞘再生的体外和体内实验模型中髓鞘修复的影响。然后在溶血磷脂酰胆碱(LPC)诱导的脱髓鞘小脑器官型切片培养物和甲硝唑诱导的脱髓鞘转基因蝌蚪中研究BTK抑制剂(BTKi;BTKi-1)的髓鞘再生作用。
通过免疫组织化学在器官型小脑切片培养物中,在溶血磷脂酰胆碱(LPC)诱导脱髓鞘之前和之后,检测BTK及其活化形式BTK-磷酸化-Y223(p-BTK)的细胞表达情况。在正常条件下,小脑切片中通过免疫标记检测到的低BTK信号与在LPC脱髓鞘切片培养物中观察到的BTK阳性细胞数量增加8.5倍形成鲜明对比。在这两种情况下,表达BTK和p-BTK的细胞中约75%是小胶质细胞,25%是星形胶质细胞。与自发恢复相比,用BTKi处理脱髓鞘切片培养物和MTZ脱髓鞘转基因蝌蚪可使髓鞘再生至少提高1.7倍。
我们的数据表明,抑制BTK是一种有前景的髓鞘修复治疗策略。